Please login to the form below

Not currently logged in
Email:
Password:

Tetra wins Meningitis UK account

Public affairs agency will promote NHS adoption of vaccine 

Meningitis UK has appointed London-based public affairs agency Tetra Strategy.

The charity is looking to build a case for the adoption of Novartis' meningitis B vaccine Bexsero by the NHS.

The drug was recently given a green light from the European Medicines Agency (EMA), which made it the first meningococcal group B vaccine licenced to protect all age groups, including infants aged over two months, in the EU.

Meningitis UK, which funds vaccine development, has engaged the agency ahead of a decision on whether to include Bexsero on the NHS's childhood immunisation programme.

This will be decided by the Joint Committee on Vaccinations and Immunisations, which plans to meet in June to discuss the vaccine.

Meningitis B infections are the most common form of bacterial meningitis in industrialised countries and currently carry a death rate of around 10 per cent.

"This meningitis B vaccine is the most important medical breakthrough in the 30 years since I lost my son to the disease," said Meningitis UK founder Steve Dayman.

"The vaccine must be made widely available through the immunisation schedule as soon as possible - any delay could mean lives lost," he added.

21st March 2013

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics